Described herein are methods of treating a disorder or disease in which aberrant Wnt signaling is implicated with a variety of compounds including Wnt inhibitor compounds. More particularly it concerns the use of an indazole compound or analogs thereof in the treatment of disorders characterized by the activation of Wnt pathway signaling (e.g. cancer abnormal cellular proliferation angiogenesis Alzheimers disease and osteoarthritis) the modulation of cellular events mediated by Wnt pathway signaling as well as genetic diseases due to mutations in Wnt signaling components.
